BioNexus Gene Lab Corp (BGLC) Cash Flow Statement
Where BGLC’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$1.8M
- Capital expenditures
- $36,971 0.5% of revenue
- Free cash flow
- −$1.9M −25.3% margin
- Returned to shareholders
- $22,112
- Change in cash
- −$400,583 cash at year-end $2.5M
Drawn to scale: where the cash came from and how it was used. Hover for values.
BGLC operating cash flow, capex and free cash flow
BGLC cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$8352016 | −$1.8M2025 | — | |
| Capital expenditures | $02016 | $36,9712025 | — | |
| Free cash flow | −$8352016 | −$1.9M2025 | — | |
| Free cash flow margin | 39.4%2017 | −25.3%2025 | −64.6 pts | |
| Operating cash flow / net income | −10.362018 | 0.012021 | +10.37 | |
| Stock-based compensation | $02022 | $794,7702025 | — | |
| Dividends paid | $6,3102020 | $22,1122025 | +28.5%/yr | |
| Capex / revenue | 292.4%2017 | 0.5%2025 | −291.9 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
BGLC cash flow by activity
BGLC net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
BGLC cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$3.0M | −$1.6M | −$2.6M | −$355,966 | $751,571 | $1.1M | −$246,469 | $26,454 | −$123,750 | −$835 |
| Depreciation & amortization | $168,307 | $153,143 | $108,423 | $105,419 | $108,215 | $101,603 | $53,332 | $40,611 | $15,031 | — |
| Stock-based compensation | $794,770 | $141,000 | $511,740 | $0 | — | — | — | — | — | — |
| Change in working capital | −$622,425 | $115,398 | $117,979 | $833,385 | −$862,248 | $102,361 | −$24,136 | −$341,145 | $439,307 | — |
| Other non-cash items | $805,573 | −$1.0M | $130,098 | −$38,810 | $11,623 | −$745,382 | $0 | $0 | $26,628 | $0 |
| Cash from operating activities | −$1.8M | −$2.2M | −$1.8M | $544,028 | $9,161 | $552,680 | −$217,273 | −$274,080 | $357,216 | −$835 |
| Investing activities | ||||||||||
| Capital expenditures | −$36,971 | −$226,989 | −$149,397 | −$54,171 | −$3,162 | −$421,621 | −$12,817 | −$39,621 | −$314,821 | $0 |
| Investments (net) | $959,610 | $418,202 | −$418,727 | −$450,498 | −$509,448 | −$78,572 | −$78,572 | −$12,080 | −$12,080 | — |
| Acquisitions & other investing | $22,112 | $226,989 | −$1.3M | $54,171 | $22,036 | $1.8M | $78,572 | $0 | −$5.0M | −$5.3M |
| Cash from investing activities | $944,751 | $418,202 | −$1.9M | −$450,498 | −$490,574 | $1.3M | −$12,817 | −$51,701 | −$5.3M | −$5.3M |
| Financing activities | ||||||||||
| Dividends paid | −$22,112 | −$68,130 | −$115,379 | −$0 | −$22,036 | −$6,310 | — | — | — | — |
| Net borrowing (repayment) | — | — | $0 | −$34,038 | −$1,920 | −$4,947 | −$17,838 | $1,442 | −$1,337 | $638 |
| Shares issued | $267,311 | $0 | $5.8M | $150,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $53,642 | $213,105 | $640,318 | $0 | −$4,266 | $6,310 | −$162,967 | $741,500 | $5.8M | $0 |
| Cash from financing activities | $298,841 | $144,975 | $6.3M | $115,962 | −$28,222 | −$4,947 | −$180,805 | $742,942 | $5.8M | $638 |
| Summary | ||||||||||
| Net change in cash | −$400,583 | −$1.6M | $3.8M | −$5,055 | −$663,773 | $1.9M | −$401,163 | $421,094 | $839,119 | −$108 |
| Cash at end of period | $2.5M | $2.9M | $5.9M | $2.1M | $2.1M | $2.8M | $859,076 | $1.3M | $839,145 | $26 |
| Free cash flow | −$1.9M | −$2.5M | −$1.9M | $489,857 | $5,999 | $131,059 | −$230,090 | −$313,701 | $42,395 | −$835 |
| Free cash flow margin | −25.3% | −25.9% | −19.6% | 4.5% | 0.0% | 1.2% | −181.2% | −147.7% | 39.4% | — |
| Capex / revenue | 0.5% | 2.4% | 1.5% | 0.5% | 0.0% | 3.7% | 10.1% | 18.7% | 292.4% | — |
| Operating cash flow / net income | — | — | — | — | 0.01 | 0.51 | — | −10.36 | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$286,451 | −$543,575 | −$1.0M | −$708,991 | −$616,172 | −$623,327 | −$348,319 | −$1.3M | $199,104 | −$103,757 | $308,463 | −$2.6M |
| Depreciation & amortization | $46,392 | $43,882 | $43,198 | $43,355 | $41,733 | $40,021 | $43,025 | $49,075 | $31,457 | $29,586 | $29,656 | $29,289 |
| Stock-based compensation | — | $794,770 | — | — | — | — | — | $141,000 | — | −$88,955 | −$88,955 | — |
| Change in working capital | −$159,213 | $176,268 | $1.2M | −$715,908 | −$112,343 | −$310,786 | $438,559 | −$744 | −$326,333 | $3,916 | $12,443 | $106,636 |
| Other non-cash items | −$23,219 | −$619,016 | $802,892 | $148,271 | −$51,125 | $70,020 | −$203,036 | −$267,071 | −$576,503 | $122,057 | −$523,516 | $1.6M |
| Cash from operating activities | −$422,491 | −$147,671 | $961,062 | −$1.2M | −$737,907 | −$824,072 | −$69,771 | −$1.4M | −$672,275 | −$37,153 | −$261,909 | −$899,345 |
| Investing activities | ||||||||||||
| Capital expenditures | −$21,259 | −$329 | −$977 | −$5,487 | −$21,459 | −$9,052 | −$4,022 | −$199,190 | −$1,833 | −$21,945 | −$937 | −$134,003 |
| Investments (net) | $416,390 | −$13,663 | −$5,100 | $994,646 | −$28,532 | −$15,646 | $488,639 | −$183,116 | $83,062 | $24,098 | −$13,752 | −$360,710 |
| Acquisitions & other investing | $21,009 | $4 | — | $1,295 | $21,459 | $9,052 | — | $160,364 | −$17,919 | $1,497 | — | $134,003 |
| Cash from investing activities | $416,140 | −$13,988 | — | $990,454 | −$28,532 | −$15,646 | — | −$221,942 | $63,310 | $3,650 | — | −$360,710 |
| Financing activities | ||||||||||||
| Dividends paid | — | −$17,200 | — | −$21,752 | — | −$59,184 | — | −$50,707 | $0 | −$8,946 | $0 | $0 |
| Net borrowing (repayment) | $19,191 | −$21,008 | — | — | $0 | $0 | — | — | — | — | — | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $5.8M |
| Other financing | −$5,584 | $97,917 | $266,544 | $55,939 | −$1,030 | $58,324 | $146,587 | −$146,275 | $175,414 | $35,876 | $11,116 | −$2,582 |
| Cash from financing activities | $13,607 | $59,709 | $266,544 | $34,187 | −$1,030 | −$860 | $146,587 | −$196,982 | $175,414 | $26,930 | $11,116 | $5.7M |
| Summary | ||||||||||||
| Net change in cash | −$1.6M | −$74,742 | $1.1M | −$164,225 | −$552,249 | −$797,528 | $161,373 | −$1.3M | −$476,487 | −$79,016 | −$217,547 | $4.4M |
| Cash at end of period | $2.4M | $4.0M | $2.5M | $2.9M | $1.5M | $2.1M | $2.9M | $4.1M | $4.0M | $4.4M | $5.9M | $6.1M |
| Free cash flow | −$443,750 | −$148,000 | $960,085 | −$1.2M | −$759,366 | −$833,124 | −$73,793 | −$1.6M | −$674,108 | −$59,098 | −$262,846 | −$1.0M |
| Free cash flow margin | −582.7% | −647.9% | 198.5% | −48.7% | −33.6% | −39.0% | −2.9% | −61.7% | −34.1% | −2.5% | −11.6% | −40.5% |
| Capex / revenue | 27.9% | 1.4% | 0.2% | 0.2% | 0.9% | 0.4% | 0.2% | 7.6% | 0.1% | 0.9% | 0.0% | 5.2% |
| Operating cash flow / net income | — | — | — | — | — | — | — | — | −3.38 | — | −0.85 | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
BGLC cash generation
In fiscal 2025 (ended December 31, 2025), BioNexus Gene Lab generated -$1.8 million of cash from operations and spent $0.0 million on capital expenditures, leaving free cash flow of -$1.9 million, −25.3% of revenue. It returned $0.0 million to shareholders through dividends ($0.0 million) and net share buybacks ($0). Cash and equivalents fell by $0.4 million over the year.
Related: BGLC income statement, BGLC balance sheet. See the BGLC stock overview for the latest quote and news.
BGLC cash flow FAQ
What is BioNexus Gene Lab's free cash flow?
BioNexus Gene Lab's free cash flow was -$1.9 million in fiscal 2025: -$1.8 million of operating cash flow minus $0.0 million of capital expenditures It was -$2.5 million a year earlier..
How much cash does BioNexus Gene Lab generate from operations?
BioNexus Gene Lab generated -$1.8 million of cash from operating activities in fiscal 2025.
How much does BioNexus Gene Lab spend on capital expenditures?
BioNexus Gene Lab spent $0.0 million on capital expenditures in fiscal 2025, 0.5% of revenue, compared with $0.2 million the year before.
How much does BioNexus Gene Lab pay in dividends?
BioNexus Gene Lab paid $0.0 million in dividends in fiscal 2025.